News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PAREXEL International (PRXL) Contributes To The Development Of Master Studies Program At University of Applied Sciences Berlin


10/19/2005 5:10:42 PM

BOSTON, April 5 /PRNewswire-FirstCall/ -- PAREXEL International Corporation , announced that PAREXEL Academy, a clinical research training and educational facility located in Berlin, Germany, has assisted in the development of a unique Clinical Trial Management postgraduate degree program. Working closely with TFH Berlin, University of Applied Sciences, the new curriculum provides comprehensive training throughout the clinical development process -- from data management, clinical monitoring, project management and regulatory compliance to quality assurance. Upon completion of the course of study, participants will be awarded a Master of Science degree in Clinical Trial Management.

Clinical trials require careful planning and management throughout every stage of the drug development process to ensure the safety of the trial participant and the accuracy of the data. Due to the complex requirements in the research, development and commercialization of novel therapeutic products, fully trained and well-qualified personnel are key success factors for bio/pharmaceutical companies.

"We were pleased to collaborate with TFH Berlin, University of Applied Sciences, to provide this unique educational opportunity in Germany," stated Dr. Heidrun Bruchmann, Director, PAREXEL Academy. "As the biopharmaceutical industry continues to grow, the demand for qualified clinical development professionals increases. The postgraduate degree in Clinical Trial Management will help to meet this demand by providing comprehensive training to individuals seeking employment with drug development companies."

"In the educational sector, too, markets are inching closer together. TFH Berlin lives up to the challenge by offering international study programs graduating Masters of Science," adds Prof. Dr. Peter Faehling from TFH. "The industries and the commerce sector in Germany and abroad have a reliable partner for technology and know-how transfer: TFH Berlin, University of Applied Sciences. Based on this, a Clinical Trial Management Masters degree opens excellent chances for the successful start of a professional career."

For further information on the PAREXEL Academy, please contact Dr. Heidrun Bruchmann at +49 (0) 30 30685 268 or heidrun.bruchmann@parexel.com.

For information on the educational degree program, contact the University's Institute for Optimization and Software at kontakt@opti-inst.de or visit http://www.tfh-berlin.de/clinicaltrialm.

TFH Berlin, University of Applied Sciences, offers 42 study programs in 8 departments for 8,500 students and has 300 full-time professors, 600 adjunct professors and 330 employees.

PAREXEL is one of the largest biopharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its information technology subsidiary, Perceptive Informatics, Inc., develops and offers a portfolio of innovative technology-based products and services that facilitate clinical drug development and are designed to decrease time to peak sales. The technology portfolio includes web-based portal solutions and tracking tools, Interactive Voice Response Systems (IVRS), Clinical Trial Management Systems (CTMS), electronic diary and investigator database solutions. Perceptive also offers advanced medical diagnostics services to assess rapidly and objectively the safety and efficacy of new drugs, biologics, and medical devices in clinical trials. PAREXEL's integrated services, therapeutic area depth and sophisticated information technology, along with its experience in global drug development and product launch services, represent key competitive strengths. Headquartered near Boston, MA, PAREXEL operates in 57 locations throughout 37 countries around the world, and has 5,050 employees. PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective owners and are hereby acknowledged. This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends", "appears", "estimates", "projects" and similar expressions are intended to identify forward-looking statements. These statements involve a number of risks and uncertainties. PAREXEL's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts; PAREXEL's dependence on certain industries and clients; PAREXEL's ability to win new business, manage growth, and attract and retain employees; PAREXEL's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry; competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of PAREXEL's Quarterly Report on Form 10-Q for the quarter ended December 31, 2003 as filed with the SEC on February 10, 2004, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent PAREXEL's estimates as of the date of this release. PAREXEL specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing PAREXEL's estimates or views as of any date subsequent to the date of this press release.

CONTACT: Kate McCorriston, Manager, Corporate Communications (610) 565-2622 x2630 kate.mccorriston@parexel.com

PAREXEL International Corporation

CONTACT: Kate McCorriston, Manager, Corporate Communications of PAREXEL,+1-610-565-2622 ext. 2630, kate.mccorriston@parexel.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES